MIRA MIRA PHARMACEUTICALS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1904286
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-42.4%
TTM EPS YoY100.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-135.7%
ROA-131.1%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets5.9%
Debt / equity0.00x
Current ratio16.97x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.50x
Accruals ratio-66.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $947,014 | $705,789 | $524,781 | $496,543 | $412,639 | $496,197 | $314,404 | $861,441 |
| SG&A expense | $465,014 | $450,330 | $578,698 | $5.33M | $904,346 | $1.05M | $1.49M | $1.58M |
| Interest expense | — | — | — | — | — | — | -$21,421 | -$38,105 |
| Net income | -$1.42M | -$1.21M | -$1.15M | -$5.98M | -$1.14M | -$1.54M | -$1.78M | -$2.40M |
| EPS (basic) | — | -0.03 | -0.03 | — | -1.18 | -0.09 | -0.11 | — |
| EPS (diluted) | -0.03 | -0.03 | -0.03 | — | -1.18 | -0.09 | -0.11 | — |
| Weighted avg. shares (diluted) | — | — | — | — | 19.27M | 16.99M | 16.65M | — |
| Banking | ||||||||
| Net interest income | $26,541 | $35,130 | $44,909 | $53,170 | $15,697 | $8,623 | $21,421 | $38,105 |
| Balance sheet | ||||||||
| Cash & equivalents | $2.50M | $3.61M | $4.82M | $6.35M | $2.64M | $730,475 | $1.21M | $2.83M |
| Short-term investments | $4.47M | $4.50M | $4.59M | $4.68M | $4.89M | — | — | — |
| Current assets | $7.23M | $8.17M | $9.43M | $11.06M | $7.60M | $832,879 | $1.36M | $2.89M |
| Total assets | $7.27M | $8.20M | $9.46M | $11.09M | $7.63M | $868,318 | $1.40M | $2.92M |
| Current liabilities | $426,176 | $40,823 | $114,761 | $702,068 | $83,926 | $298,459 | $106,173 | $723,349 |
| Total liabilities | $426,176 | $40,823 | $114,761 | $702,068 | $83,926 | $298,459 | $106,173 | $723,349 |
| Shareholders' equity | $6.84M | $8.16M | $9.35M | $10.39M | $7.55M | $569,859 | $1.29M | $2.20M |
| Shares outstanding | 42.02M | 42.02M | 42.02M | 41.94M | 39.51M | 17.39M | 16.81M | 16.56M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.30M | -$1.21M | -$1.20M | -$1.14M | -$1.10M | -$799,651 | -$1.63M | -$1.81M |
| Financing cash flow | $194,191 | $0 | -$330,607 | $4.84M | $3.01M | $323,841 | $3,381 | $493,401 |
| Stock-based compensation | $101,623 | $21,876 | $107,590 | $4.56M | $297,090 | $489,566 | $874,812 | $546,781 |
Free plan shows the latest 8 periods; Pro shows all 19 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.